Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
J Clin Neurosci. 2011 Sep;18(9):1240-4. doi: 10.1016/j.jocn.2011.01.024. Epub 2011 Jul 20.
The aim of this study was to investigate the expression of calcyclin-binding protein (also known as Siah-1-interacting protein [CacyBP/SIP]) in astrocytoma and to determine its prognostic value in overall survival of patients with glioblastoma multiforme (GBM). Tissue specimens were obtained from 77 Chinese patients who had undergone surgery for astrocytoma. The expression of CacyBP/SIP was examined by immunohistochemistry. The relationship between CacyBP/SIP and proliferating cell nuclear antigen index (PCNA) expression was investigated, and the prognostic value of CacyBP/SIP expression in patients with astrocytomas was analyzed. Of 77 tumors, 49 (63.6%) were negative for CacyBP/SIP expression. Loss of CacyBP/SIP expression was significantly associated with a high histological grade and with poor survival in univariate and multivariate analyses. Cox multivariable analysis showed that loss of CacyBP/SIP expression correlated with poor prognosis in patients with astrocytomas and was an independent prognostic factor (p<0.05). The mean survival time of patients with tumors that had lost expression of CacyBP/SIP was 25.58months (95% confidence interval [CI], 15.36-25.81months), compared to a mean survival time of 36.37months (95% CI, 27.90-44.84months) for patients with CacyBP/SIP-expressing tumors. CacyBP/SIP expression was also negatively correlated with PCNA expression in astrocytoma tissue (p<0.05). Our findings suggest that CacyBP/SIP may have an important role as a negative regulator of astrocytoma development and progression, and that CacyBP/SIP might be a useful molecular marker for predicting the prognosis of astrocytoma.
本研究旨在探讨钙调结合蛋白（也称为 Siah-1 相互作用蛋白[CacyBP/SIP]）在星形细胞瘤中的表达，并确定其在多形性胶质母细胞瘤（GBM）患者总生存期中的预后价值。收集了 77 例接受星形细胞瘤手术的中国患者的组织标本。采用免疫组织化学法检测 CacyBP/SIP 的表达。研究了 CacyBP/SIP 与增殖细胞核抗原指数（PCNA）表达之间的关系，并分析了 CacyBP/SIP 表达在星形细胞瘤患者中的预后价值。在 77 例肿瘤中，有 49 例（63.6%）CacyBP/SIP 表达阴性。CacyBP/SIP 表达缺失与组织学分级高和单因素及多因素分析中的不良生存显著相关。Cox 多变量分析显示，CacyBP/SIP 表达缺失与星形细胞瘤患者预后不良相关，是独立的预后因素（p<0.05）。CacyBP/SIP 表达缺失的患者平均生存时间为 25.58 个月（95%可信区间[CI]，15.36-25.81 个月），而 CacyBP/SIP 表达阳性的患者平均生存时间为 36.37 个月（95%CI，27.90-44.84 个月）。CacyBP/SIP 在星形细胞瘤组织中与 PCNA 表达呈负相关（p<0.05）。我们的研究结果表明，CacyBP/SIP 可能作为星形细胞瘤发生和进展的负调节因子发挥重要作用，CacyBP/SIP 可能是预测星形细胞瘤预后的有用分子标志物。
